Callan Family Office LLC Makes New Investment in Koninklijke Philips (NYSE:PHG)

Callan Family Office LLC purchased a new stake in Koninklijke Philips (NYSE:PHG) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 18,161 shares of the technology company’s stock, valued at approximately $460,000.

Other hedge funds have also modified their holdings of the company. FMR LLC grew its holdings in Koninklijke Philips by 0.6% during the third quarter. FMR LLC now owns 6,138,708 shares of the technology company’s stock valued at $200,859,000 after purchasing an additional 35,935 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Koninklijke Philips by 315.0% during the third quarter. JPMorgan Chase & Co. now owns 245,729 shares of the technology company’s stock worth $8,040,000 after purchasing an additional 186,520 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Koninklijke Philips in the 3rd quarter valued at $4,622,000. Stifel Financial Corp grew its holdings in shares of Koninklijke Philips by 16.4% in the 3rd quarter. Stifel Financial Corp now owns 195,222 shares of the technology company’s stock valued at $6,388,000 after buying an additional 27,536 shares during the period. Finally, GAMMA Investing LLC increased its position in shares of Koninklijke Philips by 6.3% in the 4th quarter. GAMMA Investing LLC now owns 10,963 shares of the technology company’s stock valued at $278,000 after buying an additional 648 shares in the last quarter. 13.67% of the stock is currently owned by institutional investors and hedge funds.

Koninklijke Philips Trading Up 1.9 %

PHG opened at $27.58 on Monday. The stock has a market capitalization of $25.93 billion, a P/E ratio of -32.84, a P/E/G ratio of 0.82 and a beta of 0.78. The company has a current ratio of 1.23, a quick ratio of 0.74 and a debt-to-equity ratio of 0.59. Koninklijke Philips has a 12 month low of $19.10 and a 12 month high of $32.91. The firm’s fifty day simple moving average is $26.51 and its 200 day simple moving average is $27.97.

Koninklijke Philips (NYSE:PHG) last issued its quarterly earnings results on Wednesday, February 19th. The technology company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.01). The firm had revenue of $5.38 billion during the quarter, compared to the consensus estimate of $5.10 billion. Koninklijke Philips had a negative net margin of 3.88% and a positive return on equity of 10.85%. As a group, research analysts anticipate that Koninklijke Philips will post 1.63 EPS for the current fiscal year.

Koninklijke Philips Cuts Dividend

The company also recently declared an annual dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 13th will be given a dividend of $0.886 per share. This represents a yield of 2.9%. The ex-dividend date is Tuesday, May 13th. Koninklijke Philips’s dividend payout ratio (DPR) is currently -89.29%.

Wall Street Analyst Weigh In

Several research firms have weighed in on PHG. UBS Group upgraded Koninklijke Philips from a “neutral” rating to a “buy” rating in a report on Thursday, February 20th. StockNews.com upgraded Koninklijke Philips from a “hold” rating to a “buy” rating in a report on Saturday. Finally, BNP Paribas upgraded Koninklijke Philips from a “neutral” rating to an “outperform” rating in a research report on Tuesday, February 25th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.